AAPG logo

AAPG Ascentage Pharma Group International

NASDAQ Global Market · Biotechnology · Healthcare

$12.44
-0.57 (-4.40%)

Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are concentrated across the United States and Mainland China. Ascentage Pharma's flagship therapeutic candidate, HQP1351 (Olverembatinib), is a BCR-ABL inhibitor …

Market Cap: $1.16Bwww.ascentage.cn

Price

No data yet.

Social Signal Score

35
5d
—
30d
35
2 mentions
—
60d
35
6 mentions
—
90d
35
6 mentions
—
news: 6

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 0Sell 0Strong Sell 0
Avg price target$45.33+264.4%
Low $40Median $45High $51
Current Consensus

Revenue

$298.88M+7696.49%
$275.2K$274.77M$549.26M$823.75M
Jun 2016Jun 2026

Analyst Estimates

FY2025
$-8.94
$-22.57–$-3.43
3 analysts
FY2026
$-3.40
$-3.80–$-3.19
6 analysts
FY2027
$-3.15
$-19.35–$47.61
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Dajun Yang
Sector
Healthcare
Industry
Biotechnology
Employees
767
Beta
0.66
Country
CN
Piotroski score
3 / 9 (Weak)
Altman Z-score
-2.64
www.ascentage.cn